Chronic Disease Control

Effect of dexmedetomidine assisted deep brain stimulation on cAMP/PKA signaling pathway in elderly patients with Parkinson′s disease

  • Chulei ZHENG ,
  • Wenbin ZHANG ,
  • Suwan HU ,
  • Qi ZHANG ,
  • Cunming LIU ,
  • Chun YANG ,
  • Siqi YANG ,
  • Jinwen LI
Expand
  • 1.Department of Anesthesiology, Brain Hospital Affiliated to Nanjing Medical University, Nanjing 210029, Jiangsu, China
    2.Department of Functional Neurosurgery, Brain Hospital Affiliated to Nanjing Medical University, Nanjing 210029, Jiangsu, China
    3.Department of Anesthesiology and Perioperative Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China

Received date: 2025-11-21

  Online published: 2026-02-25

Abstract

Objective To investigate the effect of dexmedetomidine-assisted deep brain stimulation on the cAMP/PKA signal pathway in elderly patients with Parkinson's disease. Methods A total of 150 elderly patients with Parkinson's disease who underwent deep brain stimulation (DBS) at the Affiliated Brain Hospital of Nanjing Medical University from January 2021 to January 2025 were selected as the study subjects. The enrolled patients were randomly divided into Group A (75 cases) and Group B (75 cases) using the random-number table method. In Group B, dexmedetomidine was pumped before anesthesia induction, while in Group A, an equal-volume of saline was pumped. The patients were observed for 2 weeks after the operation and followed up for 6 months. The perioperative-related indicators of the two groups were compared, including subthalamic nucleus (STN) frequency, length of bilateral subthalamic nucleus physiological signals, coordinate error, perioperative hemodynamics [before anesthesia induction (T0), after general anesthesia intubation (T1), and during anesthesia deepening (T2)], brain injury indicators (1 h before surgery, 1 d after surgery), Ramsay sedation score (before entering the operating room, before surgery, during intraoperative localization testing, and at the end of surgery), motor score of the Parkinson's syndrome scoring scale (UPDRS), cognitive function, and cAMP/PKA signaling pathway (1 h before surgery, 2 weeks after surgery). Results The recovery times of operation, unconsciousness, and spontaneous breathing in Group B were significantly shorter (P < 0.05). There were no significant differences in STN frequency, bilateral STN electrophysiological signal length, and coordinate error between Group B and Group A (P > 0.05). The mean arterial pressure (MAP) and heart rate (HR) in the T0 ~ T2 groups showed a decreasing trend. At T1 and T2, the MAP and HR in Group B were higher than those in Group A. Meanwhile, the bispectral index (BIS) in the T0 ~ T2 groups showed a trend of first decreasing and then increasing (P < 0.05). There were no significant differences in BIS and SpO2 at different times and between the two groups (P > 0.05). Compared with one hour before operation and one day after operation, the levels of serum central nervous system - specific protein (S - 100β), neuron-specific enolase (NSE), and homocysteine (Hcy) in both groups were higher, but these levels were lower in Group B. In contrast, the level of serum uric acid (UA) was lower overall, but it was higher in Group B (P < 0.05). In both groups, the Ramsay sedation scores gradually increased from the time of entering the operating room until the end of the operation. At the time of the intraoperative localization test and the end of the operation, the Ramsay sedation scores in group B were significantly higher than those in group A (P < 0.05). When compared to the scores 1 hour before the operation and 2 weeks after the operation, the Unified Parkinson's Disease Rating Scale (UPDRS) scores in both the unilateral and bilateral switch states were lower, with a more pronounced decrease in group B (P < 0.05). Similarly, the scores on the Montreal Cognitive Assessment Scale (MoCA) in both groups were higher when compared to the pre-operation (1 hour before) and 2-week post-operation scores, particularly in group B (P < 0.05). Moreover, the levels of serum cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) in both groups were higher compared to those 1 hour before the operation and 2 weeks after the operation, especially in group B (P < 0.05). Conclusions Dexmedetomidine can stabilize the perioperative hemodynamic indexes, regulate the cAMP/PKA signaling pathway, and improve the indexes of brain injury in elderly patients with Parkinson's disease undergoing deep-brain stimulation. Additionally, dexmedetomidine exhibits a favorable target-positioning effect, which shortens the operation time, the time of consciousness disappearance, and the recovery time. It also enhances the degree of sedation and improves the cognitive and motor functions of patients.

Cite this article

Chulei ZHENG , Wenbin ZHANG , Suwan HU , Qi ZHANG , Cunming LIU , Chun YANG , Siqi YANG , Jinwen LI . Effect of dexmedetomidine assisted deep brain stimulation on cAMP/PKA signaling pathway in elderly patients with Parkinson′s disease[J]. The Journal of Practical Medicine, 2026 , 42(4) : 579 -587 . DOI: 10.3969/j.issn.1006-5725.2026.04.006

References

[1] ANTENUCCI P, COLUCCI F, GOZZI A, et al. Rechargeable and Nonrechargeable Implantable Pulse Generators for Deep Brain Stimulation in Parkinson′s Disease: Long‐Term Experience[J]. Front Neurol, 2025, 2025(1): 6097313-6097313. doi: 10.1155/ANE/6097313 .
[2] LEE J E, PADILLA A H D, FOMENKO A, et al. Reduction of alpha synuclein oligomers in preclinical models of Parkinson's disease by electrical stimulation in vitro and deep brain stimulation in vivo[J]. Brain Stimul, 2024, 17(2): 166-175. doi: 10.1016/J.BRS.2024.02.005 .
[3] SCHOEN D, DEUTSCH S, MEHTA J, et al. Boundary complexity of cortical and subcortical areas predicts deep brain stimulation outcomes in Parkinson′s disease[J]. Nat Commun, 2025, 16(1): 5590-5590. doi: 10.1038/S41467-025-60695-4 .
[4] RAMíREZ Z C, MORENO F C K, MORENO G, et al. The costs and benefits of deep brain stimulation in Parkinson's disease: A review and social network analysis[J]. Arq Neuropsiquiatr, 2025, 83(7): 1-11. doi: 10.1055/S-0045-1809996 .
[5] AZGOMI F H, LOUIE H K, BATH E J, et al. Modeling and optimizing deep brain stimulation to enhance gait in Parkinson′s disease: Personalized treatment with neurophysiological insights[J]. NPJ Parkinsons Dis, 2025, 11(1): 173-173. doi: 10.1038/S41531-025-00990-5 .
[6] 熊赤, 陈鹏, 蒋曼丽, 等. 帕金森病脑深部电刺激术后基于微电极记录结果远程程控的临床疗效分析[J]. 中华神经外科杂志, 2024, 6(4): 329-334. doi: 10.3760/cma.j.cn112050-20231110-00159 .
[7] LI Z, YANG H. Intraoperative relief of resting tremor by dexmedetomidine in a patient with Parkinson's disease: A case report[J]. Asian J Surg, 2024, 47(4): 1951-1952. doi: 10.1016/J.ASJSUR.2023.12.162 .
[8] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 帕金森病基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2020, 19(1): 5-17. doi: 10.3760/cma.j.issn.1671-7368. 2020.01.003 .
[9] 刘雨睿, 王勇, 李静静, 等. 2022年美国麻醉医师协会《困难气道管理实践指南》解读[J]. 临床麻醉学杂志, 2022, 38(6): 643-647. doi: 10.12089/jca.2022.06.016 .
[10] 李其沛, 罗欣, 袁玉静, 等. 右美托咪定和舒芬太尼复合丙泊酚用于老年患者内镜逆行胰胆管造影术深度镇静的比较[J]. 临床麻醉学杂志, 2023, 39(12): 1282-1286. doi: 10.12089/jca.2023.12.009 .
[11] 万赢, 肖仁清, 赵嘉豪, 等. 帕金森病运动并发症风险分层治疗方案的疗效评价[J]. 中华医学杂志, 2022, 102(7): 491-498. doi: 10.3760/cma.j.cn112137-20210930-02204 .
[12] 刘月, 刘琦, 董惠, 等. 基于蒙特利尔认知评定量表双阈值定义的卒中后认知“恢复者”神经心理学变化研究[J]. 中国全科医学, 2023, 26(27): 3417-3422. doi: 10.12114/j.issn.1007-9572.2022.0885 .
[13] 杨杰, 邓淑坤, 袁鹏, 等. 基于肠道菌群理论探讨益生菌联合运动康复在帕金森病患者中的疗效[J]. 实用医学杂志, 2025, 41(20): 3191-3197. doi: 10.3969/j.issn.1006-5725. 2025.20.007 .
[14] SPAGNOLO D, SPITALE G. A Mixed-methods Study of Deep Brain Stimulation's Temporal Impact on Parkinson′s Disease Patients: Insights from Short-, Medium-, and Long-term Experiences[J]. Neuroethics, 2025, 18(2): 29-29. doi: 10.1007/S12152-025-09601-9 .
[15] PIWOWARSKI K, SOBSTYL M, KARAMON K. Damage to the entire deep brain stimulation system after the standard replacement of an implantable pulse generator, probably due to self-injurious behavior in a patient with advanced Parkinson's disease[J]. Postep Psychiatr Neurol, 2025, 34(2): 124-129. doi: 10.5114/PPN.2025.151784 .
[16] RAGU? M, TARLE M, MAR?INKOVI? P, et al. The Role of Preoperative Immunonutritional Scores in Predicting Complications After Subthalamic Nucleus Deep Brain Stimulation in Parkinson′s Disease[J]. J Clin Med, 2025, 14(11): 3811-3811. doi: 10.3390/JCM14113811 .
[17] PETRALITO M, TEDESCO C, PUCCIARELLI G, et al. Education Programs for Patients With Parkinson's Disease Receiving Deep Brain Stimulation: A Scoping Review[J]. West J Nurs Res, 2025, 47(8): 786-796. doi: 10.1177/01939459251341814 .
[18] LEE Y G, KWON Y H, PARK K, et al. Medication versus globus pallidus internus deep brain stimulation in Parkinson′s disease with deep learning video analysis of finger tapping[J]. Sci Rep, 2025, 15(1): 17557. doi: 10.1038/S41598-025-02098-5 .
[19] 谭丽, 马羽, 吴康, 等. 基于机器学习探讨经脑深部电刺激术治疗后帕金森病围手术期中医证候变化[J]. 中华中医药杂志, 2023, 38(12): 6128-6132. doi: 10.6038/cjg2024R0854 .
[20] 孟元元, 刘艳, 李俊, 等. 右美托咪定通过cGAS-STING通路介导的免疫调控机制对胃癌细胞恶性生物学行为的影响[J]. 中国免疫学杂志, 2024, 40(5): 945-951, 960. doi: 10.3969/j.issn.1000-484X.2024.05.008 .
[21] 王晓宁, 张丽红, 张彤, 等. 持续输注超低剂量右美托咪定对老年CAS患者血流动力学和术后认知功能的影响[J]. 中国医科大学学报, 2024, 53(3): 193-197, 206. doi: 10.12007/j.issn.0258-4646.2024.03.001 .
[22] TAKAFUMI S, HIROFUMI S, YOSHIKI U, et al. Epiretinal Membrane Surgery for a Patient with Dyskinesia Related to Parkinson's Disease Using Intravenous Dexmedetomidine Administration[J]. Case Rep Ophthalmol, 2022, 13(3): 976-980. doi: 10.1159/000527157 .
[23] BAO-PING Z, LI W, XIAN-WEI W, et al. Dexmedetomidine protects against degeneration of dopaminergic neurons and improves motor activity in Parkinson's disease mice model[J]. Saudi J Biol Sci, 2021, 28(6): 3198-3203. doi: 10.1016/J.SJBS.2021.04.013 .
[24] 余理想, 于振坤, 杨传宗, 等. 不同剂量瑞芬太尼联合右美托咪定对环杓关节脱位夹持式复位的影响[J]. 临床麻醉学杂志, 2024, 40(10): 1034-1038. doi: 10.12089/jca.2024.10.005 .
[25] MORGAN L, AMANDA D, KELLY R, et al. Treatment of Acute Delirium in a Patient with Parkinson's Disease by Transfer to the Intensive Care Unit and Administration of Dexmedetomidine[J]. J Mov Disord, 2020, 13(2): 159-162. doi: 10.14802/jmd.20005 .
[26] ANTONIO M, MIGUEL V, ELENA C, et al. Effects of dexmedetomidine on subthalamic local field potentials in Parkinson's disease[J]. Br J Anaesth, 2021, 127(2): 245-253. doi: 10.1016/J.BJA.2021.01.036 .
[27] JUNG J H, CHUNG S J, YOO H S, et al. Sex-specific association of urate and levodopa-induced dyskinesia in Parkinson's disease[J]. Eur J Neurol, 2020, 27(10): 1948-1956. doi: 10.1111/ene.14337 .
[28] 朱美琳, 程莉莉, 董有静. 右美托咪定在脑电双频指数指导及全身麻醉下帕金森病脑深部电刺激术中的应用[J]. 中国医科大学学报, 2021, 50(3): 276-279. doi: 10.12007/j.issn.0258-4646.2021.03.019 .
Outlines

/